Dr. Kapoor on LUGPA's Successes and Challenges

Deepak A. Kapoor, MD
Published: Wednesday, Jan 22, 2014

Deepak A. Kapoor, MD, former president of the Large Urology Group Practice Association (LUGPA), discusses the successes of and challenges facing LUGPA.

In recent years, membership has grown by nearly 30%, Kapoor says. Now, more than one-quarter of all urologists in the U.S. are LUGPA members and nearly one-third of independent practicing urologists are in groups that are members of LUGPA.

The greatest challenges facing LUGPA involve uncertainties around the future of healthcare. As the private sector tries to cope with healthcare changes and the expansion of Medicaid, Kapoor says, urologists have the additional burden of dealing with changes to the Medicare system.

LUGPA has been active in Washington, D.C., to tell the story of what large urology groups bring to the table, in terms of providing access at a community level in an affordable and high-quality way.

Deepak A. Kapoor, MD, former president of the Large Urology Group Practice Association (LUGPA), discusses the successes of and challenges facing LUGPA.

In recent years, membership has grown by nearly 30%, Kapoor says. Now, more than one-quarter of all urologists in the U.S. are LUGPA members and nearly one-third of independent practicing urologists are in groups that are members of LUGPA.

The greatest challenges facing LUGPA involve uncertainties around the future of healthcare. As the private sector tries to cope with healthcare changes and the expansion of Medicaid, Kapoor says, urologists have the additional burden of dealing with changes to the Medicare system.

LUGPA has been active in Washington, D.C., to tell the story of what large urology groups bring to the table, in terms of providing access at a community level in an affordable and high-quality way.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x